If you suffered losses exceeding $100,000 in AstraZeneca between between February 23, 2022 and December 17, 2024 and would ...

NEW YORK, NY / ACCESSWIRE / January 10, 2025 / If you suffered a loss on your AstraZeneca PLC (NASDAQ:AZN) investment and want to learn about a ...

Daiichi Sankyo's stock dropped 25% due to disappointing clinical data, but upcoming studies could drive a rebound for ...

A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...

A two-drug combination extended OS compared with standard first-line osimertinib for certain patients with advanced lung ...

Shares of AstraZeneca PLC AZN rose 2.18% to £109.88 Thursday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising 0.83% to 8,319.69.

U.S.-based biotech builder Mountainfield Venture Partners and China’s Keymed Biosciences have launched a new company armed ...

Alzhemier’s disease could be diagnosed up to a decade earlier after the world’s biggest study of proteins is completed. The ...

UBS has recently raised AstraZeneca PLC (AZN) stock to Neutral rating, as announced on November 20, 2024, according to Finviz. Earlier, on November 6, 2024, Deutsche Bank had raised the stock from a ...

New treatments like dotinurad provide safer, more effective solutions for millions battling gout and hyperuricemia.

A world leading UK Biobank study of half a million Brits could unlock the mysteries of ‘proteomics’ to prevent and cure ...